Pliant Therapeutics (PLRX) director Robert Iannone submits initial Form 3
Rhea-AI Filing Summary
Pliant Therapeutics, Inc. director Robert Iannone filed an initial statement of beneficial ownership on Form 3. The structured data shows no reported purchases, sales, derivative exercises, gifts, tax withholdings, or other transactions in this filing.
Positive
- None.
Negative
- None.
Key Figures
Buy transactions: 0
Sell transactions: 0
Derivative exercises: 0
+2 more
5 metrics
Buy transactions
0
buyCount in the transaction summary
Sell transactions
0
sellCount in the transaction summary
Derivative exercises
0
exerciseCount in the transaction summary
Gift transactions
0
giftCount in the transaction summary
Net buy/sell direction
neutral
netBuySellDirection in the transaction summary
Key Terms
beneficial ownership, reporting person, derivative transactions
3 terms
beneficial ownership regulatory
"filed an initial statement of beneficial ownership on Form 3"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
reporting person regulatory
"The reporting person is Robert Iannone, identified as a director"
derivative transactions financial
"The Form 3 shows no derivative transactions in the summary"
Derivative transactions are contracts whose value depends on the price or performance of something else—like stocks, bonds, currencies, interest rates or commodities. Think of them as insurance or bets about a future price: investors use them to protect against losses, lock in prices, or try to amplify returns, but they can also magnify losses, create cash demands and expose a firm to the risk that the other party won’t meet its obligation, so they can materially affect a company’s financial stability and volatility.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Form 3 filing by Pliant Therapeutics (PLRX) report?
The Form 3 filing reports that director Robert Iannone has filed an initial statement of beneficial ownership. The structured data shows no reported transactions, such as purchases, sales, or option exercises, in this filing.
Does the Pliant Therapeutics (PLRX) Form 3 show any stock purchases or sales?
No, the Form 3 for Pliant Therapeutics shows zero reported buys or sells. The transaction summary lists buyCount 0 and sellCount 0, indicating no open-market purchases or sales in this filing.
Who is the reporting person in the Pliant Therapeutics (PLRX) Form 3?
The reporting person is Robert Iannone, identified as a director of Pliant Therapeutics, Inc. He is not reported as an officer or ten percent owner in the structured filing data.
Are there any derivative transactions in the Pliant Therapeutics (PLRX) Form 3?
No, the Form 3 shows no derivative transactions. The transaction summary reports exerciseCount 0 and derivativeTransactionCount 0, and the derivative holdings section is empty in this filing.
What does the transaction summary indicate in the PLRX Form 3?
The transaction summary indicates no activity: buyCount, sellCount, exerciseCount, giftCount, and taxWithholdingCount are all 0, and netBuySellDirection is reported as neutral for this Form 3.